Navigation Links
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation

ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene, Inc., a leading biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological terrorism, announced today that new data from its recombinant butyrylcholinesterase (rBChE) research program were recently presented at the 8th International Conference on Alzheimer's and Parkinson's Diseases in Salzburg, Austria.

New research conducted by Dr. Hermona Soreq and co-workers at the Alexander Silberman Life Sciences Institute at The Hebrew University of Jerusalem, in collaboration with PharmAthene, examined the role of recombinant butyrylcholinesterase (rBChE) in the formation of amyloid plaques, which are believed to play a crucial role in the development of Alzheimer's disease.

The data presented by Drs. Soreq and Langermann, Vice President and Chief Scientific Officer for PharmAthene, show that rBChE can effectively block the formation of amyloid fibrils, precursors to plaque formation in the brain, potentially attenuating neurotoxicity. These data were substantiated by transmission electron microscopy studies, which showed that rBChE dramatically suppressed the formation of fibrils, resulting in thinner and less branched filaments than would normally occur in patients with Alzheimer's disease.

Alzheimer's disease is a progressive neurodegenerative disease, which is estimated to affect more than 4.5 million Americans. One of the hallmarks of Alzheimer's disease is the accumulation of excessive amyloid plaques in areas of the brain that control memory and cognition. Amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between neurons. A growing body of scientific evidence suggests that the accumulation of amyloid plaques and neurofibrillary tangles in the brain may play an
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmathenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
6. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
10. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
11. OXiGENE Abstracts Published in ASCO Program
Post Your Comments:
(Date:3/27/2015)... 27, 2015  The quality function within the medical ... meet quality standards at every stage of the product ... leaders also have the challenge of balancing quality and ... who don,t effectively balance these priorities risk funding and ... failure and regulatory scrutiny. For the third ...
(Date:3/27/2015)... March 27, 2015 Levi & Korsinsky announces ... (NASDAQ: OHRP ) concerning possible violations of federal ... the Company in connection with its study of the ... http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, Esq. ... by telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... WINNIPEG , March 27, 2015 /PRNewswire/ - Medicure ... Board of Directors has approved the grant of an ... management company employees and consultants of the Company pursuant ... 181,070 are set to expire on the tenth anniversary ... expire on the third anniversary of the date of ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... Terumo Heart Inc., a wholly owned subsidiary of ... the worldwide expansion of its DuraHeart(TM) Left-Ventricular Assist System ... Arusoglu, MD and Michiel Morshuis, MD, cardiothoracic surgeons at ... Diabetes Center NRW, University Hospital of the Ruhr-University of ...
... select markets worldwideNATICK, Mass., May 19 Boston ... announced the launch of the platinum chromium TAXUS(R) ... worldwide. The TAXUS Element Stent features a ... stent applications and represents the Company,s third-generation drug-eluting ...
Cached Medicine Technology:Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 2Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 3Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 2Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 3Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 5
(Date:3/28/2015)... Servpro of Paso Robles , ... report about the link between mold and asthma. Mold ... to recent medical research, may even cause asthma in ... Protection Agency, people with sensitivity to mold or mold ... trigger asthma attacks for asthma sufferers. The EPA recommends ...
(Date:3/27/2015)... Alberta (PRWEB) March 27, 2015 In her ... then, prevented her from working, Monica K. arrived at ... the mending department quiet, defensive and scared. The owners and ... & Support Services (EPSS) to offer jobs to challenged ... take patience and a willingness to begin with the end ...
(Date:3/27/2015)... 27, 2015 Bleeding is one ... percutaneous coronary intervention (PCI), resulting in increased mortality, ... “risk-treatment paradox,” in which the highest-risk PCI patients ... treated less often with bleeding avoidance strategies than ... Mid America Heart Institute asked the question whether ...
(Date:3/27/2015)... York, NY (PRWEB) March 27, 2015 Ticket Down ... in Concert in 2015. After a phenomenal and highly ... show "Nashville" will be going out on tour again in 2015 ... The tour gets underway on April 29th in New York City ... AZ at the Comerica Theatre on May 10th. , Fans of ...
(Date:3/27/2015)... 27, 2015 According to a recently ... the plate and screw market in Europe is in ... plate and screw segment. Price decreases are being seen ... almost 50% of the total European trauma device market, ... total market value, year after year. , “Such ...
Breaking Medicine News(10 mins):Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3
... WASHINGTON, Dec. 18 - In response to the,press ... E. Schumer (D-NY) of a bill -- S ... (DARA 2007)," -- which proposes to amend,the Controlled ... to minors and,create penalties to those who would ...
... America, the,fastest-growing Hispanic television network in the United States, ... this week,s broadcast of "Issues:,Caras y Voces" (Issues: Faces ... Dr. Huerta is the first Latino to assume the ... studied medicine at the University of San,Marcos and Johns ...
... Dec. 18 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... British,Columbia Supreme Court has issued a final order ... (SWX: GALN), through a wholly-owned,Canadian subsidiary, will acquire ... US$26.00 per share in cash., The transaction, ...
... 18 Alsius Corporation,(Nasdaq: ALUS ), which ... announced today that the company has,launched offers to ... opportunity, for a limited time, to exercise the ... terms of the warrants to allow holders to,receive ...
... Royalty Pharma and Northwestern,University announced today that Northwestern ... in Lyrica(R) to Royalty Pharma for $700 million,in ... A portion of the payment to Northwestern will ... chemical compound that serves as the basis for,Lyrica(R)., ...
... SAN DIEGO, Dec. 18 Pacira Pharmaceuticals, ... today announced that,David M. Stack has been ... of the Board of Directors., (Logo: ... currently the CEO and founding partner of ...
Cached Medicine News:Health News:Council for Responsible Nutrition Calls Proposed DHEA Legislation 'A Solution in Search of a Problem' 2Health News:American Cancer Society President Elmer Huerta Shares Inspirational Message on Azteca America's 'Issues: Caras Y Voces' 2Health News:Aspreva receives final court approval for acquisition by Galenica 2Health News:Aspreva receives final court approval for acquisition by Galenica 3Health News:Aspreva receives final court approval for acquisition by Galenica 4Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 2Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 3Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 4Health News:Royalty Pharma Acquires a Portion of Northwestern University's Royalty Interest in Lyrica(R) for $700 Million 2Health News:Royalty Pharma Acquires a Portion of Northwestern University's Royalty Interest in Lyrica(R) for $700 Million 3Health News:Pacira Pharmaceuticals Names David M. Stack CEO and President 2Health News:Pacira Pharmaceuticals Names David M. Stack CEO and President 3
All Day Comfort for the Lower Body...
All Purpose, General Procedure Apron...
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Medicine Products: